Mazieres et al. 16 examined 551 patients with NSCLC containing mutations in the driver genes, including KRAS, EGFR, ERBB2, ALK, ROS-1, BRAF, and RET, and 94.6% of them received ICIs following TKI or chemotherapy progression. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.